Last update 07 Mar 2025

3D Medicines, Inc. (United States)

Private Company|
Maryland, United States

Overview

Tags

Neoplasms
Hemic and Lymphatic Diseases
Nervous System Diseases
Monoclonal antibody
Small molecule drug
Nanobody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms3
Immune System Diseases3
Nervous System Diseases2
Hemic and Lymphatic Diseases2
Infectious Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug1
Nanobody1
Shared antigen vaccine1
Synthetic peptide vaccine1
Therapeutic vaccine1
Top 5 TargetCount
CD47(Cluster of differentiation 47)1
PDL1(Programmed death-ligand 1)1
COX-2(Cyclooxygenase-2)1
WT1(Wilms' Tumour 1)1

Related

4
Drugs associated with 3D Medicines, Inc. (United States)
Envafolimab
Target
PDL1
Mechanism
PDL1 inhibitors
Active Org.
Ascletis Pharma, Inc.Ascletis Pharma, Inc. [+7]
Originator Org.
Jiangsu Alphamab Biopharmaceuticals Co., LtdJiangsu Alphamab Biopharmaceuticals Co., Ltd
Active Indication
Colorectal Cancer [+21]
Inactive Indication
Advanced Sarcoma [+6]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date24 Nov 2021
Galinpepimut-S
Target
WT1
Mechanism
WT1 inhibitors [+1]
Active Org.
Memorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer Center [+4]
Originator Org.
Memorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer Center
Active Indication
Acute Myeloid Leukemia [+9]
Inactive Indication
Acute Lymphoblastic Leukemia [+4]
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
RQ-00317076
Target
COX-2
Mechanism
COX-2 inhibitors
Active Org.
Hangzhou Ruomaixing Pharmaceutical Technology Co., Ltd. [+3]
Originator Org.
RaQualia Pharma, Inc.RaQualia Pharma, Inc.
Active Indication
Pain
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with 3D Medicines, Inc. (United States)
CTR20221740
/ Active, not recruitingPhase 1
评价3D189在血液肿瘤患者中的安全性和免疫原性的I期临床研究
[Translation] Phase I clinical study evaluating the safety and immunogenicity of 3D189 in patients with hematological malignancies
CTR20220544
/ Not yet recruitingPhase 1
一项评价3D-197单药在局部晚期或转移性实体瘤和复发或难治性血液肿瘤受试者中的安全性、耐受性、药代动力学、药效动力学特征以及有效性的单臂、开放、多中心的 I 期临床研究
[Translation] A single-arm, open-label, multicenter Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic characteristics, and efficacy of 3D-197 monotherapy in subjects with locally advanced or metastatic solid tumors and relapsed or refractory hematological tumors
100 Clinical Results associated with 3D Medicines, Inc. (United States)
Login to view more data
0 Patents (Medical) associated with 3D Medicines, Inc. (United States)
Login to view more data
100 Deals associated with 3D Medicines, Inc. (United States)
Login to view more data
100 Translational Medicine associated with 3D Medicines, Inc. (United States)
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
4
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
3D-197
 ( CD47 )		Advanced Malignant Solid Neoplasm
More
Phase 1
Envafolimab
 ( PDL1 )		Microsatellite instability-high cancer
More
Phase 1
RQ-00317076
 ( COX-2 )		Pain
More
Phase 1
Galinpepimut-S
 ( WT1 )		Hematologic Neoplasms
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free